论文部分内容阅读
目的探讨贝前列素钠联合缬沙坦治疗早期糖尿病肾病患者的临床效果。方法选取2012年5月至2015年8月于辽宁省人民医院就诊的126例早期2型糖尿病肾病患者作为研究对象,按随机数字表法将其分为观察组(66例)和对照组(60例)。所有患者均给予2周糖尿病教育及糖尿病基础治疗。在此基础上,对照组患者口服缬沙坦胶囊,观察组患者联合口服缬少坦胶囊与贝前列素钠片,均持续治疗16周。比较两组患者治疗效果。结果治疗后,观察组患者的尿微量清蛋白(ALB)、尿微量清蛋白排泄率(UAER)及尿微量清蛋白/肌酐比值(ACR)水平均显著低于对照组,差异均有统计学意义(均P<0.05);两组患者治疗后血清胱抑素C(Cys C)水平较治疗前有下降趋势,但差异无统计学意义(P>0.05);而血肌酐(SCr)及尿素氮(BUN)水平比较,差异均无统计学意义(均P>0.05),且两组患者均未见明确的不良反应。结论贝前列素钠联合缬沙坦可有效降低早期糖尿病肾病患者ALB水平,改善肾脏功能。
Objective To investigate the clinical efficacy of beraprost sodium combined with valsartan in the treatment of patients with early diabetic nephropathy. Methods A total of 126 patients with early type 2 diabetic nephropathy who were treated in Liaoning Provincial People’s Hospital from May 2012 to August 2015 were selected and divided into the observation group (66 cases) and the control group (60 cases) according to the random number table method example). All patients were given 2 weeks of diabetes education and basic diabetes treatment. On this basis, patients in the control group were treated with valsartan orally, and the patients in the observation group were orally treated with valsartan and beraprost sodium tablets for 16 weeks. Compare the treatment effect of two groups of patients. Results After treatment, the urinary albumin (ALB), urinary albumin excretion (UAER) and urinary albumin / creatinine ratio (ACR) in the observation group were significantly lower than those in the control group (All P <0.05). The levels of serum Cys C in both groups decreased after treatment, but the difference was not statistically significant (P> 0.05); while serum creatinine (SCr) and urea nitrogen (BUN), the differences were not statistically significant (all P> 0.05), and no clear adverse reactions were found in both groups. Conclusions Bezoprost combined with valsartan can effectively reduce ALB level and improve renal function in patients with early diabetic nephropathy.